David B Harrell, Joseph R Purita
Pilot Study | White Paper
Harrell and Purita present the results of a series of 27 marrow aspirations using Marrow Cellution™, a bone marrow access and retrieval device designed to increase the stem/progenitor cell concentrations from the aspirate. The samples were collected under field conditions from eight separate clinicians using three different independent laboratories. The quality of the marrow aspirate was determined by performing a CFU-f test to determine the number of osteo progenitor cells.
Previous work done by a single clinician in a controlled setting demonstrated that Marrow Cellution™ delivered superior regenerative potential (as measured by CFU-f counts) to existing BMAC (Bone Marrow Aspiration Concentration) systems. This pilot study represents true field conditions as not all clinicians followed the exact same protocol with respect to heparin rinse, orientation and volume of aspirate taken.
This pilot study clearly demonstrated superior results to previously published results from multiple centrifuged-based systems. This further suggests that the Marrow Cellution™ device could provide even better results than BMAC alternatives as clinicians become more familiar and proficient with the device.
The Marrow Cellution™ System is designed to minimize and eliminate the restrictive limitations associated with “point of care” processing systems which employ inefficient traditional aspiration trocar technology and are regulated as drugs “Advanced Therapies Medicinal Products (ATMP)”. Marrow Cellution™ is a minimally invasive bone/cell enriched autograft access and retrieval system, which does not require additional manipulation or processing, it never leaves the sterile field and provides rich autograft without associated morbidity.
Visit our Marrow Cellution product page